Pages that link to "Q35551149"
Jump to navigation
Jump to search
The following pages link to Small-molecule cyclin-dependent kinase modulators (Q35551149):
Displaying 50 items.
- Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity (Q24678662) (← links)
- Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis (Q28261784) (← links)
- Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo (Q28281137) (← links)
- Cyclins: roles in mitogenic signaling and oncogenic transformation (Q28289852) (← links)
- Derricin and derricidin inhibit Wnt/β-catenin signaling and suppress colon cancer cell growth in vitro (Q28544398) (← links)
- Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells (Q28554501) (← links)
- A bifunctional regulatory element in human somatic Wee1 mediates cyclin A/Cdk2 binding and Crm1-dependent nuclear export (Q30492543) (← links)
- Homeostatic response under carcinogen withdrawal, heme oxygenase 1 expression and cell cycle association (Q33266616) (← links)
- Fusobacterium nucleatum increases collagenase 3 production and migration of epithelial cells (Q33795385) (← links)
- Cell cycle inhibition provides neuroprotection and reduces glial proliferation and scar formation after traumatic brain injury (Q33852129) (← links)
- The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity (Q33871868) (← links)
- Werner protein protects nonproliferating cells from oxidative DNA damage (Q34467601) (← links)
- Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells (Q34487091) (← links)
- Cyclin T1 overexpression induces malignant transformation and tumor growth (Q34582060) (← links)
- ATP-noncompetitive CDK inhibitors for cancer therapy: an overview (Q34756557) (← links)
- Ibulocydine is a novel prodrug Cdk inhibitor that effectively induces apoptosis in hepatocellular carcinoma cells (Q35011009) (← links)
- Staurosporine and extracellular matrix proteins mediate the conversion of small cell lung carcinoma cells into a neuron-like phenotype (Q35105889) (← links)
- Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. (Q35551099) (← links)
- Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents (Q35642631) (← links)
- A systems biology dynamical model of mammalian G1 cell cycle progression (Q35689859) (← links)
- Flavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapy (Q35800503) (← links)
- Clinical anticancer drug development: targeting the cyclin-dependent kinases (Q35959477) (← links)
- Oestrogen-mediated phosphorylation and stabilization of BRCA2 protein in breast (Q35997223) (← links)
- Recent progress in the discovery and development of cyclin-dependent kinase inhibitors (Q36120794) (← links)
- Recent developments in cancer chemotherapy oriented towards new targets. (Q36150860) (← links)
- Signal transduction pathways that inhibit hepatitis B virus replication (Q36162240) (← links)
- Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity (Q36247797) (← links)
- The Akt/PKB pathway: molecular target for cancer drug discovery (Q36313193) (← links)
- Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer (Q36448676) (← links)
- Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. (Q36461618) (← links)
- Effects of Auraptene on IGF-1 Stimulated Cell Cycle Progression in the Human Breast Cancer Cell Line, MCF-7. (Q36505765) (← links)
- Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21 (Q36612511) (← links)
- Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. (Q36680199) (← links)
- Mammalian interphase cdks: dispensable master regulators of the cell cycle (Q36796448) (← links)
- Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy (Q36822438) (← links)
- Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells (Q36868759) (← links)
- p53 and retinoblastoma pathways in bladder cancer. (Q36915110) (← links)
- Estrogen-related receptor γ is upregulated in liver cancer and its inhibition suppresses liver cancer cell proliferation via induction of p21 and p27 (Q36968020) (← links)
- Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma (Q37163806) (← links)
- The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity (Q37246747) (← links)
- Targeted therapies in the management of metastatic bladder cancer (Q37290448) (← links)
- The molecular genetics of breast cancer and targeted therapy (Q37290512) (← links)
- Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways. (Q37337951) (← links)
- Advances in preclinical small molecules for the treatment of NSCLC. (Q37489942) (← links)
- Emerging drugs for high-grade osteosarcoma (Q37778400) (← links)
- Whether to target single or multiple CDKs for therapy? That is the question (Q37788083) (← links)
- Novel potent pharmacological cyclin-dependent kinase inhibitors (Q37855812) (← links)
- Novel agents for diffuse large B-cell lymphoma (Q37858532) (← links)
- Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development (Q38088759) (← links)
- Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development (Q38120534) (← links)